COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

August 31, 2022

Study Completion Date

March 1, 2024

Conditions
Recurrent Childhood CNS TumorEpendymoma, Recurrent ChildhoodChildhood Solid Tumor
Interventions
DRUG

5 Azacytidine

Dose escalation of carboplatin combined with 5'azacytidine

Trial Locations (17)

20010

Children's National Medical Center, Washington D.C.

Unknown

Royal Children's Hospital Melbourne, Melbourne

Women's and Children's Hospital, Adelaide

Monash Children's Hospital, Clayton

John Hunter Children's Hospital, Lambton

Perth Children's Hospital, Perth

Queensland Children's Hospital, South Brisbane

Sydney Children's Hospital, Sydney

Children's Hospital at Westmead, Westmead

Alberta Children's Hospital, Calgary

BC Children's Hospital, Vancouver

McMaster Children's Hospital, Hamilton

London Health Sciences Centre, London

Children's Hospital of Eastern Ontario, Ottawa

Centre hospitalier universitaire Sainte-Justine, Montreal

Montreal Children's Hospital, Montreal

M5G1X8

Hospital for Sick Children, Toronto

All Listed Sponsors
lead

The Hospital for Sick Children

OTHER

NCT03206021 - COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors | Biotech Hunter | Biotech Hunter